| Literature DB >> 35043022 |
Zhen Luo1,2, Chunhong Ye1, Heng Xiao1,2, Jialing Yin1, Yicong Liang1, Zhihui Ruan2, Danju Luo3, Daolong Gao4, Qiuping Tan4, Yongkui Li1,2, Qiwei Zhang1,2, Weiyong Liu5, Jianguo Wu1,2,4.
Abstract
Loop-mediated isothermal amplification (LAMP) is widely used in detection of pathogenic microorganisms including SARS-CoV-2. However, the performance of LAMP assay needs further exploration in the emerging SARS-CoV-2 variants test. Here, we design serials of primers and select an optimal set for LAMP-based on SARS-CoV-2 N gene for a robust and visual assay in SARS-CoV-2 diagnosis. The limit of detectable template reaches 10 copies of N gene per 25 μL reaction at isothermal 58℃ within 40 min. Importantly, the primers for LAMP assay locate at 12 to 213 nt of N gene, a highly conservative region, which serves as a compatible test in emerging SARS-CoV-2 variants. Comparison to a commercial qPCR assay, this LAMP assay exerts the high viability in diagnosis of 41 clinical samples. Our study optimizes an advantageous LAMP assay for colorimetric detection of SARS-CoV-2 and emerging variants, which is hopeful to be a promising test in COVID-19 surveillance.Entities:
Keywords: COVID-19, coronavirus disease 2019; CRISPR, clustered regularly interspaced short palindromic repeats; Coronavirus disease 2019 (COVID-19) pandemic; Ct, threshold cycle; Emerging SARS-CoV-2 variants; IVD, in-vitro diagnosis; LAMP, Loop-mediated isothermal amplification; Loop-mediated isothermal amplification (LAMP); NGS, next-generation sequencing; POC, point-of-care; RT-qPCR, real-time reverse transcriptase quantitative polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnosis; VOC, variants of concern
Year: 2022 PMID: 35043022 PMCID: PMC8757654 DOI: 10.1016/j.ces.2022.117430
Source DB: PubMed Journal: Chem Eng Sci ISSN: 0009-2509 Impact factor: 4.311
Information of designed primers in this study.
| Primer Setting | Primer Name | Sequence (5′ to 3′) |
|---|---|---|
| PS1 | PS1-F3 | CACCCGCAATCCTGCTAAC |
| PS1-B3 | CCAGCCATTCTAGCAGGAGA | |
| PS1-FIP | TGCTCCCTTCTGCGTAGAAGCAATGCTGCAATCGTGCTACA | |
| PS1-BIP | GGCGGCAGTCAAGCCTCTTCCCTACTGCTGCCTGGAGTT | |
| PS1-LF | GCAATGTTGTTCCTTGAGGAAGT | |
| PS1-LB | TTCCTCATCACGTAGTCGCAACAGT | |
| PS2 | PS2-F3 | CCAGAATGGAGAACGCAGTG |
| PS2-B3 | CCGTCACCACCACGAATT | |
| PS2-FIP | AGCGGTGAACCAAGACGCAGGGCGCGATCAAAACAACG | |
| PS2-BIP | AATTCCCTCGAGGACAAGGCGAGCTCTTCGGTAGTAGCCAA | |
| PS2-LF | TTATTGGGTAAACCTTGGGGC | |
| PS2-LB | TCCAATTAACACCAATAGCAGTCCA | |
| PS3 | PS3-F3 | CCAGAATGGAGAACGCAGTG |
| PS3-B3 | CCGTCACCACCACGAATT | |
| PS3-FIP | AGCGGTGAACCAAGACGCAGGGCGCGATCAAAACAACG | |
| PS3-BIP | AATTCCCTCGAGGACAAGGCGAGCTCTTCGGTAGTAGCCAA | |
| PS3-LF | ATTATTGGGTAAACCTTGGGGC | |
| PS3-LB | CCAATTAACACCAATAGCAGTCCA | |
| PS4 | PS4-F3 | AGATCACATTGGCACCCG |
| PS4-B3 | CCATTGCCAGCCATTCTAGC | |
| PS4-FIP | TGCTCCCTTCTGCGTAGAAGCCAATGCTGCAATCGTGCTAC | |
| PS4-BIP | GGCGGCAGTCAAGCCTCTTCCCTACTGCTGCCTGGAGTT | |
| PS4-LF | GCAATGTTGTTCCTTGAGGAAGTT | |
| PS4-LB | GTTCCTCATCACGTAGTCGCAACA | |
| PS5 | PS5-F3 | AGATCACATTGGCACCCG |
| PS5-B3 | CCATTGCCAGCCATTCTAGC | |
| PS5-FIP | TGCTCCCTTCTGCGTAGAAGCCAATGCTGCAATCGTGCTAC | |
| PS5-BIP | GGCGGCAGTCAAGCCTCTTCCCTACTGCTGCCTGGAGTT | |
| PS5-LF | GGCAATGTTGTTCCTTGAGGAAGTT | |
| PS5-LB | GTTCCTCATCACGTAGTCGCAACA | |
| PS6 | PS6-F3 | TGGACCCCAAAATCAGCG |
| PS6-B3 | GCCTTGTCCTCGAGGGAAT | |
| PS6-FIP | CCACTGCGTTCTCCATTCTGGTAAATGCACCCCGCATTACG | |
| PS6-BIP | CGCGATCAAAACAACGTCGGCCCTTGCCATGTTGAGTGAGA | |
| PS6-LF | TTGAATCTGAGGGTCCACCA | |
| PS6-LB | TACCCAATAATACTGCGTCTTGGT | |
| PCR for CoV N genes | HCoV-OC43-F | ATGTCTTTTACTCCTGGTAAGCAATCCA |
| HCoV-OC43-B | TTATATTTCTGAGGTGTCTTCAGTAAAGGGC | |
| HCoV-NL63-F | ATGGCTAGTGTAAATTGGGCCG | |
| HCoV-NL63-B | TTAATGCAAAACCTCGTTGACAATTTCT | |
| GX_P2V-F | ATGTCTGATAATGGACCCCAAA | |
| GX_P2V-B | TACCCAATAATACTGCGTCTTGGT | |
| SADS-CoV-F | ATGGCCACTGTTAATTGGGGTG | |
| SADS-CoV-B | CTAATTAATAATCTCATCCACCATCTCAACCTCC | |
| SARS-CoV-2-F | ATGTCTGATAATGGACCCCAAAATC | |
| SARS-CoV-2-B | TTAGGCCTGAGTTGAGTCAGCACTG |
PS: Primer Setting; FIP: Forward Inner Primer; BIP: Backward Inner Primer; LF: Loop Primer Forward; LB: Loop Primer Backward; F3: F3 primer; B3: B3 primer; F: Forward; B: Backward; HCoV, human coronavirus; SADS, swine acute diarrhea syndrome.
Fig. 1Primers design for LAMP assay. (A) Principle of LAMP primers design. A set of primers contain inner primer pair (FIP: Forward Inner Primer; BIP: Backward Inner Primer), loop primer pair (LF: Loop Primer Forward; LB: Loop Primer Backward), and outer primer pair (F3: F3 primer; B3: B3 primer). Six regions were displayed as a color box. F1c means complementary sequence of F1. Primers Setting, PS. (B) Location of each set of primers in SARS-CoV-2 N gene. Six sets of primers were indicated as PS1 to PS2, respectively.
Fig. 2Determination of LAMP reaction system. A serial dilution of SARS-CoV-2 N gene DNA standards ranged from 100 to 108 copies μL−1 (1 μL each) were added in 25 μL of volume reaction for 30 min at different temperatures. The DNA products generated from indicated primer: PS1 (A), PS2 (B), PS3 (C), PS4 (D), PS5 (E), PS6 (F), were observed and quantified. M, DNA marker. A.U., Arbitrary Unit.
Fig. 3Sensitivity and specificity of the developed LAMP assay. (A) One μL of DNA standards ranged from 1 × 10 to 1 × 107 copies μL−1 were added in the 25 μL of volume reaction at 58 °C for indicated time, respectively. The DNA products were observed and quantified. A.U., Arbitrary Unit. (B) Specific sequence of amplificated DNA unit in LAMP by SP6 primers. The location of restriction enzyme site was indicated. (C) The DNA products were digested by an Xho I restriction endonuclease. (D) Each DNA sample was subjected to 25 μL of volume reaction and observed by agarose gel electrophoresis. M, DNA marker. 1. ADV-3 DNA, 2. Streptococcus pneumonia DNA, 3. Staphylococcus aureus DNA, 4. SARS-CoV-2 N gene, 5. H3N2 cDNA. (E) Each viral cDNA sample (10,000 copies) was subjected to 25 μL of volume LAMP reaction and observed by agarose gel electrophoresis. Various coronavirus N genes were amplified by PCR with specific primers. M, DNA marker. 1. HCoV-OC43, 2. HCoV-NL63, 3. GX_P2V, 4. SADS-CoV, 5. SARS-CoV-2. (F) The alignment of amplification of target region by SP6 primers of LAMP assay in SARS-CoV-2 N gene from various variants. The sequences of Alpha variant: B.1.1.7; Beta variant: B.1.351; Gamma variant: P1; Delta variant: B.1.617.2 were released from the public NCBI database (https://www.ncbi.nlm.nih.gov/). The sequences of Omicron variant: B.1.1.529 were released from the public GISAID database (https://www.gisaid.org/).
Fig. 4The colorimetric LAMP reaction system. (A) The schematic diagram for color change of MnCl2-mediated Calcein in the LAMP reaction system. (B) The colorimetric LAMP was performed at 58 °C for 40 min with the color of Calcein from orange to green after a positive reaction. (C-F) The colorimetric LAMP was performed at 58 °C for 40 min by PCR device heating (C) with positive reaction (D), or Water bath heating (E) with positive reaction (F).
Fig. 5A comparison of LAMP and qPCR assay in clinical suspected SARS-CoV-2 patients. (A) The visual LAMP assay in 41 samples from suspected SARS-CoV-2 patients and controls. The change of green in labeled samples was tested positive SARS-CoV-2. (B) DNA samples were subjected to 25 μL of volume reaction. The positive test was observed by a color change from orange to green. M, DNA marker. 1. ADV-3 DNA, 2. Streptococcus pneumonia DNA, 3. Staphylococcus aureus DNA, 4. SARS-CoV-2 N gene, 5. H3N2 cDNA. (C) Each viral cDNA sample (10,000 copies) was subjected to 25 μL of volume LAMP reaction and observed by color change from orange to green. 1. HCoV-OC43, 2. HCoV-NL63, 3. GX_P2V, 4. SADS-CoV, 5. SARS-CoV-2. (D) The melting curve of each sample in qPCR analysis. The positive test was cut-off with the threshold cycle (Ct) values over 32. The negative and positive controls were indicated by green and blue arrow, respectively. (E) The results of negative (in gray) and positive (in red) rates were displayed by LAMP and qPCR assays, respectively.
Detection of 41 clinical samples in qPCR and LAMP assays.
| Sample name | qPCR (Ct value) | LAMP (color change) | Positive (qPCR/LAMP) |
|---|---|---|---|
| 1 | Green | ||
| 2 | 32.08 | Orange | |
| 3 | 32.31 | Orange | |
| 4 | Green | ||
| 5 | 38.46 | Orange | |
| 6 | Green | ||
| 7 | Green | ||
| 8 | Green | ||
| 9 | Green | ||
| 10 | Green | ||
| 11 | 36.49 | Orange | |
| 12 | 40.00 | Orange | |
| 13 | Green | ||
| 14 | Green | ||
| 15 | Green | ||
| 16 | Green | ||
| 17 | Green | ||
| 18 | 39.27 | Orange | |
| 19 | Green | ||
| 20 | Green | ||
| 21 | Green | ||
| 22 | Green | ||
| 23 | Green | ||
| 24 | Green | ||
| 25 | 34.22 | Orange | |
| 26 | 40.00 | Orange | |
| 27 | 39.52 | Orange | |
| 28 | 38.15 | Orange | |
| 29 | 39.56 | Orange | |
| 30 | 36.64 | Orange | |
| 31 | 40.00 | Orange | |
| 32 | 35.32 | Orange | |
| 33 | Green | ||
| 34 | Green | ||
| 35 | Green | ||
| 36 | 40.00 | Orange | |
| 37 | 37.05 | Orange | |
| 38 | 32.29 | Orange | |
| 39 | Green | ||
| 40 | Green | ||
| 41 | 37.62 | Orange |
Ct, threshold cycle; +, positive; −, negative; qPCR positive: cut-off with Ct value > 32.00; LAMP positive: green color.
Comparison of qPCR and LAMP tests for SARS-CoV-2 infection diagnosis in suspected patients.
| SARS-CoV-2 N gene | Negative (N) | Positive (N) | Positive Rate (%) | Total (N) | Concordance rate (%) | χ2 |
|---|---|---|---|---|---|---|
| LAMP | 18 | 23 | 56.1 | 41 | 95.1 | 0.658 |
| qPCR | 20 | 21 | 48.8 |
N, number of cases; χ2, Chi-square test for the difference between LAMP and qPCR assays. P < 0.05 was defined as statistically significant.